Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

Colorectal Cancer Clinical Trial

Official title: Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Using the Sleeping Beauty System to Express T Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors

Status Recruiting

Clinical Trial Summary

Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumors

Clinical Trial Description

This is a prospective observational, non-interventional study for the long-term follow-up of safety and efficacy for subjects who have received autologous T cells engineered using the Sleeping Beauty System to express T cell receptors (TCRs) reactive against cancer-specific mutations (neoantigen specific TCR-T cells). In this study, subjects will be followed for up to 15 years after initial TCR-T cell drug product administration for evaluation of delayed adverse events (AEs). ;

Related Conditions & MeSH terms

• Adenocarcinoma of Lung
• Adenosquamous Cell Lung Cancer
• Cholangiocarcinoma
• Colorectal Cancer
• Gynecologic Cancer
• Lung Neoplasms
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Ovarian Neoplasms
• Ovary Neoplasm
• Pancreatic Cancer
• Squamous Cell Lung Cancer

• NCT number: NCT05292859
• Study type: Observational
• Source: Alaunos Therapeutics
• Contact: Sandra Sinclair, MHA/Ed,RN
• Phone: 832-622-1699
• Email: ssinclair@alaunos.com
• Status: Recruiting
• Start date: October 1, 2022
• Completion date: June 2039